Tags

Type your tag names separated by a space and hit enter

Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system.
Bull Exp Biol Med. 2006 Nov; 142(5):598-600.BE

Abstract

Peptide anxiolytic selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) applied intraperitoneally in doses of 0.01, 0.1, 1.0, and 10.0 mg/kg to mice reduces behavioral manifestations of dopaminergic system induced by apomorphine in the verticalization test. This effect was comparable to that of atypical antipsychotic olanzapine in near-therapeutic doses (0.1 and 1.0 mg/kg, intraperitoneally) and was blocked with nonselective opioid receptor antagonist naloxone (10 mg/kg, intraperitoneally). Radioreceptor assay showed that selank did not displace nonselective D2-dopamine receptor antagonist (3)H-spiperone (EC50>100 microM) and delta- and micro-opioid receptor ligand 3H-DADLE (EC50>40 microM) from specific binding sites on rat brain membranes. It is hypothesized that the revealed behavioral effect of selank is mediated by its modulating effect on the endogenous opioid system and specifically, by its effect on activity of enkephalin-degrading enzymes.

Links

Aggregator Full Text

Authors+Show Affiliations

Meshavkin VK
Research Center of Mental Health, Russian Academy of Medical Sciences, Moscow. meshavkin@ rcmh.msk.ru
Kost NV
No affiliation info available
Sokolov OY
No affiliation info available
Zolotarev YA
No affiliation info available
Myasoedov NF
No affiliation info available
Zozulya AA
No affiliation info available

MeSH

AnimalsAnti-Anxiety AgentsApomorphineBehavior, AnimalBenzodiazepinesDopamineEnkephalin, Leucine-2-AlanineMaleMiceNaloxoneOlanzapineOligopeptidesReceptors, Dopamine D2Receptors, Opioid, muSpiperoneStereotyped Behavior

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17415472

Citation

Meshavkin, V K., et al. "Naloxone-blocked Depriming Effect of Anxiolytic Selank On Apomorphine-induced Behavioral Manifestations of Hyperfunction of Dopamine System." Bulletin of Experimental Biology and Medicine, vol. 142, no. 5, 2006, pp. 598-600.
Meshavkin VK, Kost NV, Sokolov OY, et al. Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system. Bull Exp Biol Med. 2006;142(5):598-600.
Meshavkin, V. K., Kost, N. V., Sokolov, O. Y., Zolotarev, Y. A., Myasoedov, N. F., & Zozulya, A. A. (2006). Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system. Bulletin of Experimental Biology and Medicine, 142(5), 598-600.
Meshavkin VK, et al. Naloxone-blocked Depriming Effect of Anxiolytic Selank On Apomorphine-induced Behavioral Manifestations of Hyperfunction of Dopamine System. Bull Exp Biol Med. 2006;142(5):598-600. PubMed PMID: 17415472.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system. AU - Meshavkin,V K, AU - Kost,N V, AU - Sokolov,O Yu, AU - Zolotarev,Yu A, AU - Myasoedov,N F, AU - Zozulya,A A, PY - 2007/4/7/pubmed PY - 2007/6/20/medline PY - 2007/4/7/entrez SP - 598 EP - 600 JF - Bulletin of experimental biology and medicine JO - Bull Exp Biol Med VL - 142 IS - 5 N2 - Peptide anxiolytic selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) applied intraperitoneally in doses of 0.01, 0.1, 1.0, and 10.0 mg/kg to mice reduces behavioral manifestations of dopaminergic system induced by apomorphine in the verticalization test. This effect was comparable to that of atypical antipsychotic olanzapine in near-therapeutic doses (0.1 and 1.0 mg/kg, intraperitoneally) and was blocked with nonselective opioid receptor antagonist naloxone (10 mg/kg, intraperitoneally). Radioreceptor assay showed that selank did not displace nonselective D2-dopamine receptor antagonist (3)H-spiperone (EC50>100 microM) and delta- and micro-opioid receptor ligand 3H-DADLE (EC50>40 microM) from specific binding sites on rat brain membranes. It is hypothesized that the revealed behavioral effect of selank is mediated by its modulating effect on the endogenous opioid system and specifically, by its effect on activity of enkephalin-degrading enzymes. SN - 0007-4888 UR - https://www.unboundmedicine.com/medline/citation/17415472/Naloxone_blocked_depriming_effect_of_anxiolytic_selank_on_apomorphine_induced_behavioral_manifestations_of_hyperfunction_of_dopamine_system_ L2 - https://dx.doi.org/10.1007/s10517-006-0428-1 DB - PRIME DP - Unbound Medicine ER -